Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immutep Ltd (IMM.AX)

Immutep Ltd (IMM.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Immutep Ltd 264 George Street Level 32, Australia Square Sydney NSW 2000 AUS

https://www.immutep.com P: +61 283157003 F: +61 285691880

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Key Statistics

Overview:

Market Capitalization, $K 64,844
Shares Outstanding, K 1,473,721
% of Institutional Shareholders 14.34%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -61,434 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -3,075 K

Growth:

1-Year Return -83.40%
3-Year Return -81.28%
5-Year Return -90.33%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.06
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 11/05/19

IMM.AX Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % -61.85%
Return-on-Assets % -50.93%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales 15.79
Price/Book 0.66
Book Value/Share 0.07
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.